NEUROCRINE BIOSCIENCES INC (NBIX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 3.37B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $3.37B | (m) | (m) |
| 2026-03-31 | (m) | $3.10B | $56.70M | (m) |
| 2025-12-31 | (m) | $2.86B | $52.10M | (m) |
| 2025-09-30 | (m) | $2.68B | $43.80M | (m) |
| 2025-06-30 | (m) | $2.51B | $37.80M | (m) |
| 2025-03-31 | (m) | $2.41B | $35.70M | (m) |
| 2024-12-31 | (m) | $2.36B | $34.00M | (m) |
| 2024-09-30 | (m) | $2.24B | $33.20M | (m) |
| 2024-06-30 | (m) | $2.12B | $36.40M | (m) |
| 2024-03-31 | (m) | $1.98B | $38.70M | (m) |
| 2023-12-31 | (m) | $1.89B | $39.70M | (m) |
| 2023-09-30 | (m) | $1.78B | $38.90M | (m) |
| 2023-06-30 | (m) | $1.67B | $33.80M | (m) |
| 2023-03-31 | (m) | $1.60B | $27.10M | (m) |
| 2022-12-31 | (m) | $1.49B | $23.20M | (m) |
| 2022-09-30 | (m) | $1.39B | (m) | (m) |
| 2022-06-30 | (m) | $1.30B | (m) | (m) |
| 2022-03-31 | (m) | $1.21B | (m) | (m) |
| 2021-12-31 | (m) | $1.13B | (m) | (m) |
| 2021-09-30 | (m) | $1.07B | (m) | (m) |
| 2021-06-30 | (m) | $1.03B | (m) | (m) |
| 2021-03-31 | (m) | $1.05B | (m) | (m) |
| 2020-12-31 | (m) | $1.05B | (m) | (m) |
| 2020-09-30 | (m) | $1.04B | (m) | (m) |
| 2020-06-30 | (m) | $1.01B | (m) | (m) |
| 2020-03-31 | (m) | $886.79M | (m) | (m) |
| 2019-12-31 | (m) | $788.09M | (m) | (m) |
| 2019-09-30 | (m) | $675.57M | (m) | (m) |
| 2019-06-30 | (m) | $605.23M | $5.82M | (m) |
| 2019-03-31 | (m) | $518.56M | $5.07M | (m) |
| 2018-12-31 | (m) | $451.24M | $4.89M | (m) |
| 2018-09-30 | (m) | $414.26M | (m) | (m) |
| 2018-06-30 | (m) | $323.28M | (m) | (m) |
| 2018-03-31 | (m) | $232.71M | (m) | (m) |
| 2017-12-31 | (m) | $161.63M | (m) | (m) |
| 2017-09-30 | (m) | $67.11M | (m) | (m) |
| 2017-06-30 | (m) | $6.33M | (m) | (m) |
| 2017-03-31 | (m) | $0.00 | (m) | (m) |
| 2016-12-31 | (m) | $15.00M | (m) | (m) |
| 2016-09-30 | (m) | $15.00M | (m) | (m) |
| 2016-06-30 | (m) | $15.00M | (m) | (m) |
| 2016-03-31 | (m) | $15.00M | (m) | (m) |
| 2015-12-31 | (m) | $19.77M | (m) | (m) |
| 2015-09-30 | (m) | $19.77M | (m) | (m) |
| 2015-06-30 | (m) | $19.77M | (m) | (m) |
| 2015-03-31 | (m) | $19.77M | (m) | (m) |
| 2014-12-31 | (m) | $0.00 | (m) | (m) |
| 2014-09-30 | (m) | $730.00K | (m) | (m) |
| 2014-06-30 | (m) | $1.46M | (m) | (m) |
| 2014-03-31 | (m) | $2.19M | (m) | (m) |
| 2013-12-31 | (m) | $2.92M | (m) | (m) |
| 2013-09-30 | (m) | $24.14M | (m) | (m) |
| 2013-06-30 | (m) | $32.76M | (m) | (m) |
| 2013-03-31 | (m) | $42.60M | (m) | (m) |
| 2012-12-31 | (m) | $53.14M | (m) | (m) |
| 2012-09-30 | (m) | $42.30M | (m) | (m) |
| 2012-06-30 | (m) | $74.58M | (m) | (m) |
| 2012-03-31 | (m) | $76.17M | (m) | (m) |
| 2011-12-31 | (m) | $77.41M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $33.50M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $2.95M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |